SPOTLIGHT: Bayer prepares to launch Phase III

Germany's Bayer says it will push ahead with a Phase III trial of BAY 59-7939 for venous thromboembolism following analysis of positive data from a Phase II study. The pivotal trial should get underway in the fourth quarter. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.